Platelet Derived Growth Factor Receptor (PDGFR)

Product #

Description

Biochem/physiol Actions

Add to Cart

D5943 2-(3,4-Dimethoxy-benzoylamino)-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid amide ≥98% (HPLC), solid Flt-3 (fms-related tyrosine kinase 3) inhibitor
SML0334 DMPQ dihydrochloride ≥98% (HPLC) DMPQ is a potent selective inhibitor of human vascular beta-type platelet derived growth factor receptor tyrosine kinase (PDGFR?) with IC50 = 80 nM. It is > 100-fold selective over EGFR, erbB2, p56, protein kinase A and protein kinase C.
J4649 JNJ-10198409 ≥98% (HPLC), solid JNJ-10198409 is a potent ATP-competitive inhibitor of Platelet-Derived Growth Factor receptor tyrosine kinase (PDGF-RTK) with both antiangiogenic and a direct tumor cell antiproliferative activity. It is selective for PDGF-β kinase with IC50 values of 4.2 nM for PDGF-β and 45 nM for PDGF-α kinase.
SML1161 Ki11502 ≥98% (HPLC) Ki11502 is a potent, ATP-competitive multikinase inhibitor that is selective for PDGF receptor. Ki11502 inhibits malignant hematopoietic cells proliferation and induces their apoptosis. Ki11502 is effective against colorectal cancer SW480 cell line.
SML0966 PLX647 ≥98% (HPLC) PLX647 is a potent and specific dual inhibitor of the receptor tyrosine kinases FMS and KIT. PLX647 blocks activation of macrophages, osteoclasts and mast cells in both cell based and in vivo inflammation models.
PZ0338 Toceranib ≥98% (HPLC) Toceranib (SU11654) is a protein tyrosine kinase inhibitor that selectively targets stem cell factor receptor c-kit, including all forms of mutant Kit, as well as PDGFR and VEGFR. Toceranib exhibited Ki values of 5 nM for PDGFR and 6 nM for VEGFR. Toceranib phosphate is approved for use in mast cell cancer in dogs.
SML0071 Trapidil ≥98% (HPLC) Trapidil is an antiplatelet agent that acts in part as a phosphodiesterase inhibitor and as a competitive inhibitor of the platelet-derived growth factor (PDGF) receptor. Trapidil, with its vasodilator and NO releasing effect may have some potential to diminish the tissue injury. Trapidil suppresses platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell (VSMC) proliferation by inhibiting Raf-1/extracellular signal-regulated kinase (ERK) via cAMP/protein kinase A (PKA). In addn. to cAMP/PKA activation, trapidil inhibits RhoA/ROCK activation.
T182 Tyrphostin A9 solid Tyrphostin A9 is a PDGF receptor tyrosine kinase inhibitor that can induce apoptosis in cancer cells, inhibit the growth of vascular smooth cells and block calcium release-dependent phosphorylations.